Circulating calprotectin - the power to assess inflammation

Newsletter 1/2025

It’s clear that the awareness of the clinical impact of circulating calprotectin continues to grow. The increasing global demand has driven routine clinical adoption and a surge in scientific evaluation across a range of inflammatory conditions.

We have also expanded our clinical collaborations, with both prospective and retrospective studies already underway in 2025, and we look forward to share news about calprotectin in clinical settings going forward.

Circulating calprotectin – the early biomarker in inflammation

Calprotectin, a neutrophilic heterodimer comprised of S100A8 and S100A9, is released as part of the innate immune response. Its rapid release and direct correlation with inflammation make it a reliable marker across various infectious, autoimmune, and autoinflammatory conditions.

Calprotectin’s ability to accurately track even subclinical inflammation is making it invaluable in monitoring inflammatory rheumatic diseases (IRDs), including rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). A continuously growing body of scientific evidence, supported by multiple clinical trials, has led to inclusion of calprotectin measurements in guidelines issued by EULAR, ACR, and PReS.

Calprotectin is also emerging as a valuable biomarker in emergency medicine, offering early detection of bacterial infections due to its rapid kinetics and release into circulation, even before systemic inflammatory responses develop.

Beckman Coulter partner to launch Gentian GCAL® Calprotectin Immunoassay

We are pleased to announce the launch of the GCAL^® Calprotectin Immunoassay with Beckman Coulter Diagnostics to its clinical chemistry platforms. This partnership marks an important development for the calprotectin testing market, bringing this innovative biomarker to a broad audience and ensuring easy and fast routine access for laboratories and clinicians.

Calprotectin in RA and JIA – Promising 2024 study results

Recent studies highlight calprotectin's potential in predicting treatment response for RA and JIA, supporting its role as a key biomarker. Recent publications demonstrate how calprotectin measurements aid in optimising treatment decisions and monitoring disease activity.

Your One-Stop page for calprotectin resources

We are pleased to announce the relaunch of calprotectin.com, our dedicated webpage for professionals in the field of rheumatic diseases. This resource, along with the dedicated GCAL^® product page, in-depth background articles, and our circulating literature service, provides a comprehensive overview of calprotectin and its role in rheumatic conditions.

New learnings on calprotectin

CORA 2025 - International Congress on Controversies in Rheumatology and Autoimmunity

At the 8th International Congress on Controversies in Rheumatology and Autoimmunity, we joined global experts to discuss emerging data on circulating calprotectin and the GCAL^® assay. The event provided an excellent platform to explore its diagnostic potential and growing relevance in autoimmune conditions.

ISICEM 2025 – International Symposium on Intensive Cardiovascular Care

At the 44th ISICEM, a significant focus was placed on the role of neutrophils, including the formation of neutrophil extracellular traps (NETs) and their contribution to organ damage. Calprotectin as biomarker for neutrophil activation is key player in the conversation on sepsis and innate immune activation. Its relevance to disease severity was underlined, supporting its role in advancing precision medicine for critically ill patients.

21st International Vasculitis Workshop (2024) outcome

This workshop highlighted the role of serum calprotectin (S100A8/A9) in vasculitis and paediatric rheumatic diseases. New research showed strong links between calprotectin levels and disease activity, reinforcing its value as a biomarker for monitoring and guiding treatment decisions. Read more here.

GCAL® - Plasma & serum calprotectin: Easy implementation in routine

The GCAL^® assay is designed for the quantitative determination of calprotectin in plasma and serum, intended as an aid in detection and assessment of inflammation and inflammatory response to infections. As the first turbidimetric assay available since 2019, GCAL^® offers distinct advantages:

Advanced technology: PETIA assay on clinical chemistry platforms using avian antibodies, which minimises interference from rheumatoid factor and HAMA antibodies

Versatility: Compatible with a wide range of automated clinical chemistry analysers

Regulatory compliance: CE-marked, IVDR certified, and registered in multiple regions*

Ready-to-use format: Complete kit components - including calibrators and dedicated controls - are available in two sizes to meet the needs of both small and high-volume laboratories

We hope you found this newsletter both informative and inspiring as we continue our journey to advance patient care through innovative biomarker solutions. Stay tuned for more updates and insights throughout 2025!

Get in touch

Interested in plasma and serum calprotectin? Want to know more? Please send an email to marketing@gentian.com or fill out the form below:

* This webpage may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances

Circulating calprotectin - the power to assess inflammation